vaginal Isosorbaid mononitrat and vaginal estradiol and Placebo effect on cervix ripening. Disorders related to long gestation and high birth weight
Conditions
Interventions
Treatment - Drugs
Placebo
Intervention 1: From all of mothers, we will obtain a NST, After ensuring fetal heart rate pattern, patients randomized block design are divided into three groups. At the vaginal isosorbide mononitrat
From all of mothers, we will obtain a NST, After ensuring fetal heart rate pattern, patients randomized block design are divided into three groups. At the vaginal isosorbide mononitrate group, 1 table
From all of mothers, we will obtain a NST, After ensuring fetal heart rate pattern, patients randomized block design are divided into three groups.
At the vaginal estradiol group, 1 tablet 25 micro g
From all of mothers, we will obtain a NST, After ensuring fetal heart rate pattern, patients randomized block design are divided into three groups.
At the Placebo group, 1 Placebo tablet placed in th
Sponsors
Deputy Director of Research and Technology of Ardabil University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 35 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: singleton pregnancy; cephalic presentation; intact membranes; BS less than 6; the result of normal fetal health monitoring; lack of uterine contractions; the absence of systemic problems in the history; clinical examination; age 15 to 35 Exclusion criteria: women with preeclampsia; history of previous cesarean; active genital herpes; poly Hydramnious; placenta previa or placental abruption risk; membrane rupture; history of Cardiac or respiratory disease; the presence of any contra indication for labor induction; systolic blood pressure less than 90 mmHg
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bishop score (cervix ripening). Timepoint: at the visit, 12 hours and 24 hours later. Method of measurement: Vaginal examination (According to Williams reference table to determine the Bishop score). | — |
Secondary
| Measure | Time frame |
|---|---|
| From active phase to full dilatation. Timepoint: During the study. Method of measurement: Observation and examination.;From full dilatation to delivery. Timepoint: During the study. Method of measurement: Observation and examination.;From Induction to active phase. Timepoint: During the study. Method of measurement: Observation and examination.;Delivery. Timepoint: During the study. Method of measurement: Observation and examination.;Maternal side effects (headache, nausea, vomiting, and dizziness). Timepoint: During the study. Method of measurement: Observation and examination.;The consequences of neonatal (first and fifth minute Apgar score, gender and birth weight, infant hospitalized in the Intensive Care Unit, Meconium defecation). Timepoint: During the study. Method of measurement: Observation and examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNushin Chamheidar
Ardabil University of Medical Sciences
Outcome results
None listed